{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=12&sponsor=Pfizer",
    "query": {
      "sponsor": "Pfizer",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 3276,
    "total_pages": 328,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=13&sponsor=Pfizer&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=11&sponsor=Pfizer&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T19:32:59.868Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00790049",
      "title": "A Safety Study of ARRY-371797 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ARRY-371797, p38 inhibitor; oral",
          "type": "DRUG"
        },
        {
          "name": "Placebo; oral",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Array Biopharma, now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 40,
      "start_date": "2008-10-31",
      "completion_date": "2009-01-21",
      "has_results": false,
      "last_update_posted_date": "2022-05-05",
      "last_synced_at": "2026-10-27T19:32:59.868Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00790049"
    },
    {
      "nct_id": "NCT02942355",
      "title": "Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Female Breast Carcinoma",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2016-12-07",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-10-27T19:32:59.868Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02942355"
    },
    {
      "nct_id": "NCT03839355",
      "title": "Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Apixaban",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2018-12-19",
      "completion_date": "2020-12-15",
      "has_results": true,
      "last_update_posted_date": "2021-03-16",
      "last_synced_at": "2026-10-27T19:32:59.868Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03839355"
    },
    {
      "nct_id": "NCT00098748",
      "title": "Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Optimized Background Therapy (OBT)",
          "type": "DRUG"
        },
        {
          "name": "maraviroc (UK-427,857)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 190,
      "start_date": "2004-11",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2010-12-07",
      "last_synced_at": "2026-10-27T19:32:59.868Z",
      "location_count": 44,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Hayward",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00098748"
    },
    {
      "nct_id": "NCT00282984",
      "title": "Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Smoking Cessation"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "Varenicline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "35 Years to 75 Years"
      },
      "enrollment_count": 714,
      "start_date": "2006-02",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2017-04-05",
      "last_synced_at": "2026-10-27T19:32:59.868Z",
      "location_count": 3,
      "location_summary": "Hartford, Connecticut • Boston, Massachusetts • Madison, Wisconsin",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00282984"
    },
    {
      "nct_id": "NCT07508228",
      "title": "A Study to Understand How a Study Medicine Called PF-07328948 is Absorbed and Processed in the Body of Healthy Male Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Oral [14C]PF-07328948",
          "type": "DRUG"
        },
        {
          "name": "Oral Unlabeled PF-07328948",
          "type": "DRUG"
        },
        {
          "name": "IV [14C]PF-07328948",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "MALE",
        "summary": "18 Years to 64 Years · Male only"
      },
      "enrollment_count": 8,
      "start_date": "2026-04-03",
      "completion_date": "2026-07-10",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-27T19:32:59.868Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07508228"
    },
    {
      "nct_id": "NCT00628745",
      "title": "Transthyretin Amyloidosis Outcome Survey (THAOS)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Transthyretin Gene Mutations",
        "Transthyretin Amyloidosis"
      ],
      "interventions": [
        {
          "name": "None. Observational Study.",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6718,
      "start_date": "2008-01-04",
      "completion_date": "2023-06-19",
      "has_results": true,
      "last_update_posted_date": "2024-11-22",
      "last_synced_at": "2026-10-27T19:32:59.868Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00628745"
    },
    {
      "nct_id": "NCT00800267",
      "title": "A Study of Glaucoma or Ocular Hypertension in Patients Within the United States",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "latanoprost 0.005%",
          "type": "DRUG"
        },
        {
          "name": "fixed combination latanoprost-timolol",
          "type": "DRUG"
        },
        {
          "name": "timolol 0.5%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 418,
      "start_date": "1997-07",
      "completion_date": "1999-06",
      "has_results": false,
      "last_update_posted_date": "2021-02-18",
      "last_synced_at": "2026-10-27T19:32:59.868Z",
      "location_count": 53,
      "location_summary": "Anaheim, California • Sacramento, California • San Francisco, California + 39 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00800267"
    },
    {
      "nct_id": "NCT00974311",
      "title": "Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Castration-Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1199,
      "start_date": "2009-09-30",
      "completion_date": "2017-11-02",
      "has_results": true,
      "last_update_posted_date": "2018-12-11",
      "last_synced_at": "2026-10-27T19:32:59.868Z",
      "location_count": 98,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00974311"
    },
    {
      "nct_id": "NCT00141271",
      "title": "A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Geodon (Ziprasidone)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 536,
      "start_date": "2005-07",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2021-03-25",
      "last_synced_at": "2026-10-27T19:32:59.868Z",
      "location_count": 72,
      "location_summary": "Birmingham, Alabama • Dana Point, California • La Mesa, California + 60 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dana Point",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00141271"
    }
  ]
}